{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:19:54Z","timestamp":1792639194362,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.chest.2020.04.046","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T03:42:13Z","timestamp":1588822933000},"page":"1651-1664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung Disease"],"prefix":"10.1016","volume":"158","author":[{"given":"Christopher S.","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana A.","family":"Shlobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chest.2020.04.046_bib1","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1183\/13993003.02316-2014","article-title":"Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review","volume":"46","author":"Raghu","year":"2015","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.chest.2020.04.046_bib2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/MCP.0000000000000599","article-title":"Pulmonary hypertension due to interstitial lung disease","volume":"25","author":"King","year":"2019","journal-title":"Curr Opin Pulm Med"},{"issue":"1","key":"10.1016\/j.chest.2020.04.046_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2014.06.014","article-title":"A\u00a0consensus document for the selection of lung transplant candidates: 2014\u2014an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation","volume":"34","author":"Weill","year":"2015","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"1","key":"10.1016\/j.chest.2020.04.046_bib5","doi-asserted-by":"crossref","first-page":"1801914","DOI":"10.1183\/13993003.01914-2018","article-title":"Pulmonary hypertension in chronic lung disease and hypoxia","volume":"53","author":"Nathan","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2020.04.046_bib6","series-title":"Primary Pulmonary Hypertension: Report on a WHO Meeting","author":"Hatano","year":"1975"},{"key":"10.1016\/j.chest.2020.04.046_bib7","unstructured":"Nathan SD, Barnett S, King CS, et\u00a0al. Impact of the new definition for pulmonary hypertension in patients with lung disease. Eur Respir J. (Under review)"},{"key":"10.1016\/j.chest.2020.04.046_bib8","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000114246","article-title":"Serial development of pulmonary hypertension in patients with IPF","volume":"76","author":"Nathan","year":"2008","journal-title":"Respiration"},{"issue":"3","key":"10.1016\/j.chest.2020.04.046_bib9","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1378\/chest.129.3.746","article-title":"Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis","volume":"129","author":"Lettieri","year":"2006","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2020.04.046_bib10","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1183\/09031936.00107206","article-title":"Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant","volume":"30","author":"Shorr","year":"2007","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.chest.2020.04.046_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141911","article-title":"Pulmonary hypertension in patients with chronic fibrosing idiopathic interstitial pneumonias","volume":"10","author":"Hoeper","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.chest.2020.04.046_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018775056","article-title":"Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups","volume":"8","author":"Chebib","year":"2018","journal-title":"Pulm Circ"},{"issue":"1","key":"10.1016\/j.chest.2020.04.046_bib13","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00545-2018","article-title":"Prevalence and impact of WHO group 3 pulmonary hypertension in advanced idiopathic nonspecific interstitial pneumonia","volume":"52","author":"King","year":"2018","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.chest.2020.04.046_bib14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1183\/09031936.00010414","article-title":"A\u00a0haemodynamic study of pulmonary hypertension in chronic hypersensitivity pneumonitis","volume":"44","author":"Oliveira","year":"2014","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2020.04.046_bib15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1440-1843.2010.01909.x","article-title":"Exercise capacity in idiopathic pulmonary fibrosis: the effect of pulmonary hypertension","volume":"16","author":"Boutou","year":"2011","journal-title":"Respirology"},{"issue":"2","key":"10.1016\/j.chest.2020.04.046_bib16","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.rmed.2008.11.012","article-title":"Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis","volume":"103","author":"Song","year":"2009","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.chest.2020.04.046_bib17","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1378\/chest.128.4.2393","article-title":"Pulmonary hypertension in patients with idiopathic pulmonary fibrosis","volume":"128","author":"Nadrous","year":"2005","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.chest.2020.04.046_bib18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1183\/09031936.00115511","article-title":"Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis","volume":"40","author":"Judge","year":"2012","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.chest.2020.04.046_bib19","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.healun.2017.02.016","article-title":"The Giessen Pulmonary Hypertension Registry: survival in pulmonary hypertension subgroups","volume":"36","author":"Gall","year":"2017","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"6","key":"10.1016\/j.chest.2020.04.046_bib20","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1159\/000345221","article-title":"Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis","volume":"85","author":"Kimura","year":"2013","journal-title":"Respiration"},{"key":"10.1016\/j.chest.2020.04.046_bib21","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1378\/chest.06-1466","article-title":"Significance of PAP and diffusion capacity of the lung as prognosticator in patients with IPF","volume":"131","author":"Hamada","year":"2007","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2020.04.046_bib22","first-page":"413","article-title":"Group III pulmonary hypertension: pulmonary hypertension associated with lung disease\u2014epidemiology, pathophysiology, and treatments","volume":"34","author":"Klinger","year":"2016","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.chest.2020.04.046_bib23","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1172\/JCI33338","article-title":"Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration","volume":"119","author":"Zhao","year":"2009","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.chest.2020.04.046_bib24","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1164\/rccm.200608-1153CC","article-title":"Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots","volume":"175","author":"Nathan","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2020.04.046_bib25","first-page":"7","article-title":"Pulmonary hypertension in idiopathic pulmonary fibrosis: a review","volume":"26","author":"Corte","year":"2009","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.chest.2020.04.046_bib26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/MCP.0000000000000190","article-title":"Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis","volume":"21","author":"King","year":"2015","journal-title":"Curr Opin Pulm Med"},{"issue":"3","key":"10.1016\/j.chest.2020.04.046_bib27","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1378\/chest.06-2485","article-title":"Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis","volume":"131","author":"Nathan","year":"2007","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2020.04.046_bib28","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.chest.2019.01.035","article-title":"A\u00a0prospective evaluation of the diagnostic accuracy of the physical examination for pulmonary hypertension","volume":"155","author":"Braganza","year":"2019","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2020.04.046_bib29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.healun.2018.09.011","article-title":"Survival in pulmonary hypertension due to chronic lung disease: influence of low diffusuion capacity of the lungs for carbon monoxide","volume":"38","author":"Rose","year":"2019","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"10","key":"10.1016\/j.chest.2020.04.046_bib30","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.rmed.2006.02.004","article-title":"The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis","volume":"100","author":"Lettieri","year":"2006","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.chest.2020.04.046_bib31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1440-1843.2010.01877.x","article-title":"Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis","volume":"16","author":"Swigris","year":"2011","journal-title":"Respirology"},{"issue":"7","key":"10.1016\/j.chest.2020.04.046_bib32","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/resp.13066","article-title":"CT-determined pulmonary artery to aorta ratio as a predictor of elevated pulmonary artery pressure and survival in idiopathic pulmonary fibrosis","volume":"22","author":"Yagi","year":"2017","journal-title":"Respirology"},{"issue":"5","key":"10.1016\/j.chest.2020.04.046_bib33","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1183\/13993003.01532-2015","article-title":"Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis","volume":"47","author":"Shin","year":"2016","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2020.04.046_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.chest.2019.06.033","article-title":"Right ventricular to left ventricular ratio at CT pulmonary angiogram predicts mortality in interstitial lung disease","volume":"157","author":"Bax","year":"2020","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.chest.2020.04.046_bib35","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/crj.13059","article-title":"Multimodal noninvasive prediction of pulmonary hypertension in IPF","volume":"13","author":"Sonti","year":"2019","journal-title":"Clin Respir J"},{"issue":"1","key":"10.1016\/j.chest.2020.04.046_bib36","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01311-2017","article-title":"A\u00a0scoring system to predict the elevation of mean pulmonary arterial pressure in idiopathic pulmonary fibrosis","volume":"51","author":"Furukawa","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2020.04.046_bib37","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.rmed.2008.03.022","article-title":"Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idopathic pulmonary fibrosis","volume":"102","author":"Nathan","year":"2008","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.chest.2020.04.046_bib38","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/crj.12608","article-title":"Pulmonary hypertension in advanced lung diseases: echocardiography as an important part of patient evaluation for lung transplantation","volume":"12","author":"Nowak","year":"2018","journal-title":"Clin Respir J"},{"key":"10.1016\/j.chest.2020.04.046_bib39","article-title":"Clinical determinants and prognostic implications of right ventricular dysfunction in pulmonary hypertension caused by chronic lung disease","volume":"8","author":"Prins","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.chest.2020.04.046_bib40","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.chest.2018.01.022","article-title":"Exercise-induced pulmonary hypertension: transplating pathophysiological concepts into clinical practice","volume":"154","author":"Naeije","year":"2018","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2020.04.046_bib41","doi-asserted-by":"crossref","first-page":"1801015","DOI":"10.1183\/13993003.01015-2018","article-title":"Exercise pulmonary haemodynamic response predicts outcomes in fibrotic lung disease","volume":"52","author":"Jose","year":"2018","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2020.04.046_bib42","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000114246","article-title":"Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis","volume":"76","author":"Nathan","year":"2008","journal-title":"Respiration"},{"issue":"1","key":"10.1016\/j.chest.2020.04.046_bib43","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1086\/690017","article-title":"Chronic use of PAH-specific therapy in World Health Organization Group III pulmonary hypertension: a systemic review and meta-analysis","volume":"7","author":"Prins","year":"2017","journal-title":"Pulm Circ"},{"issue":"9337","key":"10.1016\/j.chest.2020.04.046_bib44","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(02)11024-5","article-title":"Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial","volume":"360","author":"Ghofrani","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.chest.2020.04.046_bib45","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1164\/ajrccm.160.2.9810008","article-title":"Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis","volume":"160","author":"Olschewski","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.chest.2020.04.046_bib46","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1002110","article-title":"A\u00a0controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis","volume":"363","author":"Zisman","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2020.04.046_bib47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.humpath.2006.06.007","article-title":"Pulmonary vascular lesions in end-stage idiopathic pulmonary fibrosis: histopathologic study on lung explant specimens and correlations with pulmonary hemodynamics","volume":"38","author":"Colombat","year":"2007","journal-title":"Hum Pathol"},{"issue":"4","key":"10.1016\/j.chest.2020.04.046_bib48","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1183\/09031936.00024113","article-title":"Treatment of pulmonary hypertension in interstitial lung disease: do not throw out the baby with the bath water","volume":"41","author":"Cottin","year":"2013","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2020.04.046_bib49","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1164\/rccm.200705-732OC","article-title":"BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis","volume":"177","author":"King","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2020.04.046_bib50","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1164\/rccm.201011-1874OC","article-title":"BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis","volume":"184","author":"King","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.chest.2020.04.046_bib51","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1183\/09031936.00104612","article-title":"Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial","volume":"42","author":"Raghu","year":"2013","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.chest.2020.04.046_bib52","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-158-9-201305070-00003","article-title":"Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial","volume":"158","author":"Raghu","year":"2013","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.chest.2020.04.046_bib53","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02596-2017","article-title":"The unmet need of pulmonary hypertension in idiopathic pulmonary fibrosis","volume":"51","author":"Cottin","year":"2018","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.chest.2020.04.046_bib54","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1164\/rccm.201403-0446OC","article-title":"Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia","volume":"190","author":"Corte","year":"2014","journal-title":"Am J Resp Crit Care Med"},{"issue":"4","key":"10.1016\/j.chest.2020.04.046_bib55","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1183\/09031936.00213911","article-title":"Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial","volume":"41","author":"Hoeper","year":"2013","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.chest.2020.04.046_bib56","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S2213-2600(19)30250-4","article-title":"Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study","volume":"7","author":"Nathan","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.chest.2020.04.046_bib57","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1056\/NEJMoa1811737","article-title":"Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis","volume":"379","author":"Kolb","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.chest.2020.04.046_bib58","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00408-017-0081-7","article-title":"Inhaled treprostinil in pulmonary hypertension associated with lung disease","volume":"196","author":"Faria-Urbina","year":"2018","journal-title":"Lung"},{"issue":"2","key":"10.1016\/j.chest.2020.04.046_bib59","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/thoraxjnl-2013-204150","article-title":"Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis","volume":"69","author":"Saggar","year":"2014","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.chest.2020.04.046_bib60","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1378\/chest.06-2101","article-title":"Sildenafil improves walk distance in idiopathic pulmonary fibrosis","volume":"131","author":"Collard","year":"2007","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2020.04.046_bib61","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00408-009-9209-8","article-title":"Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis","volume":"188","author":"Jackson","year":"2010","journal-title":"Lung"},{"issue":"4","key":"10.1016\/j.chest.2020.04.046_bib62","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1183\/09031936.00149205","article-title":"Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study","volume":"29","author":"Gunther","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2020.04.046_bib63","doi-asserted-by":"crossref","first-page":"633S","DOI":"10.1378\/chest.132.4_MeetingAbstracts.633a","article-title":"A\u00a0randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of iloprost inhalation in adults with abnormal pulmonary arterial pressure and exercise limitation associated with idiopathic pulmonary fibrosis","volume":"132","author":"Krowka","year":"2007","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.chest.2020.04.046_bib64","first-page":"282","article-title":"Treatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung disease","volume":"17","author":"Mittoo","year":"2010","journal-title":"Can Respir J"},{"issue":"6","key":"10.1016\/j.chest.2020.04.046_bib65","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1358\/dot.2008.44.6.1220138","article-title":"Bosentan in systemic sclerosis","volume":"44","author":"Heresi","year":"2008","journal-title":"Drugs Today (Barc)"},{"issue":"2-3","key":"10.1016\/j.chest.2020.04.046_bib66","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.vph.2009.04.002","article-title":"Sildenafil therapy in secondary pulmonary hypertension: is there benefit in prolonged use?","volume":"51","author":"Chapman","year":"2009","journal-title":"Vascul Pharmacol"},{"issue":"8","key":"10.1016\/j.chest.2020.04.046_bib67","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/j.1440-1843.2010.01860.x","article-title":"The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease","volume":"15","author":"Corte","year":"2010","journal-title":"Respirology"},{"issue":"2","key":"10.1016\/j.chest.2020.04.046_bib68","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1755-5922.2011.00279.x","article-title":"ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension","volume":"30","author":"Badesch","year":"2012","journal-title":"Cardiovasc Ther"},{"issue":"5","key":"10.1016\/j.chest.2020.04.046_bib69","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/resp.12294","article-title":"Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors","volume":"19","author":"Zimmermann","year":"2014","journal-title":"Respirology"},{"issue":"5","key":"10.1016\/j.chest.2020.04.046_bib71","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1183\/13993003.02307-2014","article-title":"Severe pulmonary hypertension in lung disease: phenotypes and response to treatment","volume":"46","author":"Brewis","year":"2015","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.chest.2020.04.046_bib72","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1378\/chest.11-2490","article-title":"Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies","volume":"142","author":"Le Pavec","year":"2012","journal-title":"Chest"},{"issue":"suppl 3","key":"10.1016\/j.chest.2020.04.046_bib73","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2362.2006.01695.x","article-title":"Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease","volume":"36","author":"Ahmadi-Simab","year":"2006","journal-title":"Eur J Clin Invest"},{"issue":"7","key":"10.1016\/j.chest.2020.04.046_bib74","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/art.27466","article-title":"Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis","volume":"62","author":"Seibold","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.chest.2020.04.046_bib75","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.3899\/jrheum.110499","article-title":"Effect of bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study","volume":"38","author":"Furuya","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.chest.2020.04.046_bib76","series-title":"Bardoxolone methyl\u00a0evaluation in patients with pulmonary hypertension (PH)\u2014LARIAT. NCT02036970. ClinicalTrials.gov","year":"2014"},{"issue":"3","key":"10.1016\/j.chest.2020.04.046_bib77","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.chest.2019.05.004","article-title":"Rare lung disease research: National Heart, Lung, and Blood Institute's commitment to partnership and progress","volume":"156","author":"Vuga","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.chest.2020.04.046_bib78","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1378\/chest.11-0449","article-title":"Gene expression profiling in the lungs of patients with PH associated with PF","volume":"141","author":"Mura","year":"2012","journal-title":"Chest"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369220308722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369220308722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:23:02Z","timestamp":1757924582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369220308722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0012369220308722"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2020.04.046","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung Disease","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2020.04.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}